BioVaxys Technology (XCNQ:BIOV) ROCE % : -1,640.88% (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioVaxys Technology's annualized ROCE % for the quarter that ended in Jul. 2023 was -1,640.88%.

BioVaxys Technology ROCE % Historical Data

The historical data trend for BioVaxys Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology ROCE % Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

ROCE %

-380.70

-22.53

-72.64

-110.26

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
ROCE %	Get a 7-Day Free Trial															-55.12	-136.31	-	-2,229.18	-1,640.88

BioVaxys Technology ROCE % Calculation

BioVaxys Technology's annualized ROCE % for the fiscal year that ended in Oct. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	-4.082	/	( ( (8.504 - 0.327)	+	(0.866 - 1.639) )	/ 2 )
	=	-4.082	/	( (8.177	+	-0.773)	/ 2 )
	=	-4.082	/	3.702
	=	-110.26 %

BioVaxys Technology's ROCE % of for the quarter that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jul. 2023 )		(Q: Apr. 2023 )		(Q: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jul. 2023 )		(Q: Apr. 2023 )		(Q: Jul. 2023 )
	=	-2.248	/	( ( (2.653 - 1.755)	+	(1.413 - 2.037) )	/ 2 )
	=	-2.248	/	( ( 0.898	+	-0.624 )	/ 2 )
	=	-2.248	/	0.137
	=	-1,640.88 %

(1) Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

BioVaxys Technology (XCNQ:BIOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioVaxys Technology ROCE % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (XCNQ:BIOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

Executives

James Passin

Director, Senior Officer

BioVaxys Technology (XCNQ:BIOV) Headlines

No Headlines